Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=3&sort=-funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=-funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=-funder" }, "data": [ { "type": "Grant", "id": "10245", "attributes": { "award_id": "1K24AI167805-01A1", "title": "Mentoring Patient-Oriented Research on Advances to Optimize Engagement in HIV Care", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6828, "first_name": "Rosemary G", "last_name": "McKaig", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-08", "end_date": "2027-07-31", "award_amount": 192450, "principal_investigator": { "id": 26191, "first_name": "Katerina A", "last_name": "Christopoulos", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Dr. Christopoulos is an infectious disease physician and Associate Professor of Medicine in the Division of HIV, ID, and Global Medicine at UCSF. Her research over the past ten years has focused on improving engagement in HIV care for underserved urban populations by identifying those at risk for poor engagement, understanding barriers to and facilitators of engagement, and developing interventions to support engagement. She has mentored numerous early career investigators, including pre-doctoral students, post-doctoral fellows, and junior faculty but now seeks the protected time of the K24 award to increase the depth and scope of her mentorship, undertake dedicated mentorship skills training, and grow her program of patient oriented research. The COVID-19 pandemic has highlighted further the need for rigorous evaluation of the impact of innovations in HIV care delivery to ensure their use does not widen HIV health disparities. In this application, Dr. Christopoulos proposes a comprehensive mentoring, research, and career development plan to promote the equitable delivery of HIV care and treatment in a post-COVID landscape. Leveraging the infrastructure of the CFAR Network of Integrated Clinical Systems (CNICS) and her role as UCSF site PI, the research proposed in this application seeks to investigate the impact of advances in HIV care and treatment, i.e., telehealth, long- acting injectable antiretroviral therapy, on retention and viral suppression. In addition to the resources of CNICS, which include a mentoring core, Dr. Christopoulos will utilize an implementation science R01 on long- acting injectable antiretroviral therapy, training and career resources at UCSF, and a robust network of multidisciplinary collaborators to provide mentees with training opportunities, preliminary data, and platforms on which to build new research. Through the guidance of an experienced senior mentoring team, formal didactics, and mentee feedback, she will augment and formalize her mentoring abilities and approach with additional training in mentoring across differences and supporting under-represented minority (URM) investigators, building an equity focus in her mentoring as well as her research. The K24 is instrumental to achieving her long-term career goals of becoming an international leader on the topic of engagement in HIV care and maximizing the impact of her scientific pursuits by training the next generation of researchers focused on optimizing HIV care engagement.", "keywords": [ "Address", "Adherence", "Affect", "Applications Grants", "Area", "COVID-19 pandemic", "Caring", "Clinic", "Clinic Visits", "Clinical", "Code", "Communicable Diseases", "Communities", "Data", "Data Collection", "Development", "Development Plans", "Drug resistance", "Ensure", "Environment", "Faculty", "Failure", "Feedback", "Future", "Goals", "HIV", "Health", "Healthcare", "Home", "Homelessness", "Impact evaluation", "Infrastructure", "Injectable", "Injections", "International", "Intervention", "Interview", "Learning", "Measures", "Medicine", "Mentors", "Mentorship", "Methods", "Mid-Career Clinical Scientist Award (K24)", "Midcareer Investigator Award in Patient-Oriented Research", "Modality", "Modeling", "Outcome", "Patient Outcomes Assessments", "Patients", "Pattern", "Perception", "Persons", "Physicians", "Postdoctoral Fellow", "Provider", "Qualitative Research", "Quality of Care", "Research", "Research Methodology", "Research Personnel", "Resources", "Risk", "Role", "Roter", "Sampling", "Site", "Social support", "Surveys", "Survival Analysis", "System", "Systems Analysis", "Telephone", "Time", "Training", "Underrepresented Minority", "Urban Population", "Viral", "Visit", "Work", "antiretroviral therapy", "base", "care delivery", "career", "career development", "data infrastructure", "doctoral student", "drug development", "ethnic minority", "experience", "health disparity", "health equity", "housing instability", "implementation science", "improved", "improved outcome", "innovation", "interest", "mid-career faculty", "minority investigator", "multidisciplinary", "multilevel analysis", "next generation", "pandemic disease", "patient oriented", "patient oriented research", "patient-clinician communication", "pill", "post-COVID-19", "pre-doctoral", "programs", "psychosocial", "racial and ethnic", "research and development", "shared decision making", "skills", "skills training", "social stigma", "substance use", "success", "telehealth", "telehealth systems", "therapy development", "training opportunity", "treatment strategy", "urban underserved", "video visit", "ward" ], "approved": true } }, { "type": "Grant", "id": "5502", "attributes": { "award_id": "1R21LM013638-01", "title": "Development of a vaccine informatics system and its application to identifying the impact of vaccine debate on immunization rates during a global pandemic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Library of Medicine (NLM)" ], "program_reference_codes": [], "program_officials": [ { "id": 19149, "first_name": "ALAN", "last_name": "VANBIERVLIET", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-08-01", "end_date": "2023-07-31", "award_amount": 191420, "principal_investigator": { "id": 19150, "first_name": "Young Anna", "last_name": "Argyris", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 19151, "first_name": "Pang-Ning", "last_name": "Tan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 521, "ror": "https://ror.org/05hs6h993", "name": "Michigan State University", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Vaccine debate has been on social media for more than a decade, and a surge of anti-vaccine activities on social media has been detected during prior disease outbreaks. Nonetheless, how this debate changes and impacts the uptake rates for crucial vaccines during the COVID-19 pandemic remains unknown. The long-term goal is to counteract the negative impact of misinformation on digital platforms that threatens public health. The overall objectives of this application are to develop a publicly accessible vaccine informatics system to track vaccine debate, and to test the impact of vaccine debate on COVID-19 (if developed by 2021), flu, and HPV immunization rates during the onset of a global pandemic. The central hypothesis is that vaccine debate will increase and become more negative during the pandemic, leading to lower vaccine uptake rates. The rationale for this project is that discovering how vaccine debate changes and influences vaccine uptake rates during a pandemic will be critically important for managing and preventing disease spread. The central hypothesis will be tested by pursuing two specific aims: 1) Develop a vaccine informatics system to identify the frequency and valence of vaccine debate during and following the pandemic compared to the pre-pandemic baseline; and 2) Apply this system to identify the causal impact of vaccine debate on immunization rates during the pandemic. Under the first aim, ~1 million social media posts will be collected, and a deep-learning algorithm for classifying multimodal social media posts will be developed. This algorithm will address potential bias and noise in human annotations of vaccine debate that is increasingly politicized. The classification results will be tabulated in a Web portal so that daily and weekly statistics about pro- and anti-vaccine posts will be readily available. Under the second aim, a multimethod approach will be proposed that resolves the current barriers in research on vaccine refusal. This approach will use a survey of 2,000 individuals who represent the US population. The survey responses will be combined with the respondents' prior engagement with vaccine debate retrospectively collected from social media. These engagement data will be then classified by the machine- learning algorithm developed in Aim 1. This research is innovative because it proposes a robust co-teaching framework for addressing noisy human annotations of vaccine debate. It also proposes a statistical modeling technique that involves heterogenous metrics obtained from a multi-method approach for hypothesis testing. These innovations are timely and urgent as the current time presents a rare opportunity to identify the impact of vaccine debate on public health during the onset of a global pandemic. The feasibility of this proposed research is clear from the solid preliminary datasets collected from 2018-2020 that establish the pre-pandemic baseline. The proposed research is significant because it will produce a public barometer of vaccine debate and provide a methodological breakthrough in uncovering the reasoning behind refusing crucial vaccines during the global pandemic.", "keywords": [ "Address", "Adolescent", "Affect", "Algorithms", "Belief", "COVID-19", "COVID-19 pandemic", "COVID-19 vaccine", "Child", "Classification", "Collection", "Data", "Data Set", "Disease", "Disease Outbreaks", "Dose", "Drug Industry", "Educational process of instructing", "Epidemic", "Frequencies", "Fright", "Goals", "Government", "Health", "Health Care Costs", "Human", "Human Papilloma Virus Vaccination", "Human Papilloma Virus Vaccine", "Human Papilloma Virus-Related Malignant Neoplasm", "Human Papillomavirus", "Immunization", "Individual", "Informatics", "Informed Consent", "Intervention", "Knowledge", "Knowledge Discovery", "Lead", "Machine Learning", "Malignant neoplasm of cervix uteri", "Measles", "Medicine", "Methodology", "Methods", "Misinformation", "Modeling", "Morbidity - disease rate", "Movement", "Mumps", "Neighborhoods", "Noise", "Outcome", "Performance", "Population", "Prevention", "Public Health", "Research", "Respondent", "Risk", "Rubella", "Safety", "Solid", "Statistical Models", "Surveys", "System", "Techniques", "Testing", "Time", "Training", "Vaccination", "Vaccines", "complex data", "cost", "data management", "deep learning", "deep learning algorithm", "digital", "distrust", "flu", "geographic difference", "heterogenous data", "image processing", "influenza epidemic", "influenza virus vaccine", "innovation", "insight", "machine learning algorithm", "multimodality", "natural language", "novel vaccines", "pandemic disease", "prevent", "response", "social media", "statistics", "uptake", "vaccine acceptance", "vaccine development", "vaccine discovery", "vaccine trial", "web portal" ], "approved": true } }, { "type": "Grant", "id": "10285", "attributes": { "award_id": "1R41DC020415-01", "title": "Adaptive olfactory threshold testing in the clinical assessment of anosmia", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Deafness and Other Communication Disorders (NIDCD)" ], "program_reference_codes": [], "program_officials": [ { "id": 22552, "first_name": "Roger", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-10", "end_date": "2023-07-31", "award_amount": 252118, "principal_investigator": { "id": 25143, "first_name": "STEVEN D", "last_name": "MUNGER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1909, "ror": "", "name": "REDOLYNT, LLC", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "Smell disorders are highly impactful in daily life. Gas leaks and spoiled food are undetectable dangers. Adequate nutrition is compromised as food become unpalatable without the core contribution smell plays in flavor perception. Affected individuals also feel disconnected from the world and other people, contributing to an increased incidence of depression. Smell disorders may also be early indicators of other serious health problems such as rhinosinusitis, skull base tumors, cerebrospinal fluid leaks, or neurological diseases such as Alzheimer's disease, Parkinson's disease or multiple sclerosis. Smell disorders are also much more common than most people believe, with one major pre-COVID-19 study finding that over 12% Americans age 40 and older had hyposmia (a reduced ability to smell) or anosmia (an inability to smell). However, despite substantial prevalence and significant health impacts, smell disorders remain routinely underdiagnosed, in part because routine olfactory screening is not a part of primary care. A major impediment to incorporating objective, validated smell tests in routine healthcare is that the current options are too time consuming and/or expensive. Thus, a new option is needed if smell testing is to be embraced by medical providers as a part of routine screening, analogous to the ubiquitous Snellen eye chart and handheld audiometer used in many primary care clinics. Roughly a third of US adults receive an annual physical or preventive care visit. Including smell tests in such visits would result in over 75 million tests per year. When an olfactory disorder is diagnosed or suspected, it typically results in referrals to specialists (e.g., neurology, otolaryngology) and in procedures such as surgeries, imaging, and endoscopy that are billable to health insurance. Thus, we expect that a low cost, rapid smell test would provide a substantial return on investment for healthcare systems. To address this unmet need for a robust, rapid, inexpensive, cross-cultural test of olfactory function that can be administered in varied settings, we designed the Adaptive Olfactory Measure of Threshold (ArOMa-T). The ArOMa-T includes multiple concentrations of a single odorant spaced over several log units of concentration and encapsulated in peel- and-burst labels on a foldable card. The card is paired with an adaptive algorithm, implemented via a website or app, that guides the patient through a sequence of odorant concentrations where each is selected based on prior responses. By skipping non-informative concentrations, this test rapidly determines the patient's odor detection threshold. The ArOMa-T can be self-administered and produced inexpensively at scale. In this proposal, we will pursue three Specific Aims to move the ArOMa-T towards commercialization: we will (1) compare the performance of the ArOMa-T against other validated smell tests; (2) develop an accompanying application for real-time processing of the adaptive algorithm; and (3) assess provider experience with the test and app in a real world clinical setting. Together, these studies will establish the technical merit, feasibility and commercial potential of the ArOMa-T.", "keywords": [ "Address", "Adult", "Affect", "Affordable Care Act", "Age", "Algorithms", "Alzheimer&apos", "s Disease", "American", "Anosmia", "COVID-19", "COVID-19 associated anosmia", "Cerebrospinal Fluid", "Clinic", "Clinical", "Clinical assessments", "Code", "Collaborations", "Consumption", "Detection", "Devices", "Diagnosis", "Diagnostic Reagent Kits", "Discrimination", "Encapsulated", "Endoscopy", "Europe", "Eye", "Feedback", "Food", "Functional disorder", "Gases", "Health", "Health Insurance", "Health Personnel", "Healthcare", "Healthcare Systems", "Image", "Incidence", "Individual", "Instruction", "Insurance", "Insurance Carriers", "Investments", "Joint Commission on Accreditation of Healthcare Organizations", "Label", "Language", "Life", "Measures", "Medical", "Medicare", "Mental Depression", "Multiple Sclerosis", "National Health and Nutrition Examination Survey", "Neurology", "Notification", "Odors", "Olfaction Disorders", "Operative Surgical Procedures", "Otolaryngology", "Output", "Pamphlets", "Paper", "Parkinson Disease", "Patient Self-Report", "Patients", "Pennsylvania", "Perception", "Performance", "Persons", "Phenylethyl Alcohol", "Play", "Prevalence", "Preventive care", "Primary Health Care", "Procedures", "Provider", "Quality of life", "Safety", "Secure", "Self Administration", "Series", "Skull Base Neoplasms", "Smell Perception", "Specialist", "Tablets", "Test Result", "Testing", "Time", "Training", "Universities", "Visit", "Visual impairment", "Work", "base", "cognitive load", "commercialization", "cost", "design", "experience", "hyposmia", "memory recall", "nervous system disorder", "nutrition", "olfactory disorder", "olfactory threshold", "pain scale", "pandemic disease", "performance tests", "programs", "response", "rhinosinusitis", "routine screening", "screening", "smartphone Application", "smell test", "web site" ], "approved": true } }, { "type": "Grant", "id": "5312", "attributes": { "award_id": "1R21AI171827-01", "title": "Small molecule inhibitors targeting the SARS-CoV-2 pathogenicity factor Nsp1", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 18663, "first_name": "DIPANWITA", "last_name": "Basu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-06-07", "end_date": "2024-05-31", "award_amount": 257283, "principal_investigator": { "id": 18664, "first_name": "Morkos Adel Ibrahim", "last_name": "Henen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 18665, "first_name": "Anna-Lena", "last_name": "Steckelberg", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has caused great harm to human life and the worldwide economy. Almost 2 years after the emergence of its etiological agent SARS-CoV-2, there are still very few available antiviral drugs. The situation is further aggravated by the emergence of new viral variants that might render available antiviral therapeutics and vaccines less effective in the future. This calls for the development of diverse antiviral strategies, aimed at targeting as many different viral pathways as possible. Here we explore for the first time the possibility to create inhibitors of the viral protein Nsp1 to fight SARS-CoV-2 infection. Nsp1 is a major virulence factor that functions by restricting host gene expression to inhibit antiviral signaling. We have recently identified nine putative inhibitors of Nsp1 function by quantitative high throughput screening. We propose an in-depth structural and functional characterization of the identified compounds to explore their capability to be developed into potent antiviral drugs. In aim 1 we will use NMR spectroscopy to identify the pharmacophore and binding site(s) of the small molecule inhibitors on Nsp1. It is the goal of aim 1 to determine the minimal ligand structural features necessary for Nsp1 inhibition. We will also test commercially available analogs to interrogate which chemical moieties can increase binding and inhibition. In aim 2 we will explore which functions of Nsp1 are targeted by small molecule inhibition. By combining an array of complementary biochemical and cell-based assays, we will interrogate the effect of small molecule inhibition on ribosome binding, mRNA degradation, and mRNA translation. It is the goal of aim 2 to identify the mechanism of inhibition to aid future compound optimization. By pharmacologically targeting selective functions of Nsp1, we might also gain new biological insight into the coronaviral host-shutoff pathway. Overall, these studies should provide insight into the structure and mechanism of potential small molecule inhibitors of SARS-CoV-2 Nsp1, laying the foundation for future chemical optimization of lead compounds with the goal to develop new potent anti-coronaviral drugs.", "keywords": [ "2019-nCoV", "Affinity", "Antiviral Agents", "Attenuated", "Binding", "Binding Sites", "Biochemical", "Biological", "Biological Assay", "COVID-19", "COVID-19 pandemic", "Cells", "Cessation of life", "Chemicals", "Coronavirus", "Data", "Development", "Enzymes", "Etiology", "Foundations", "Future", "Gene Expression", "Genetic Translation", "Goals", "Human", "Infection", "Knowledge", "Lead", "Life", "Ligands", "Light", "Molecular", "NMR Spectroscopy", "Pathway interactions", "Peptide Hydrolases", "Pharmaceutical Preparations", "Pharmacology", "Production", "Proteins", "RNA-Directed RNA Polymerase", "Reporter", "Respiratory Disease", "Ribosomal Interaction", "Ribosomes", "SARS coronavirus", "SARS-CoV-2 infection", "SARS-CoV-2 inhibitor", "Signal Transduction", "Structure", "Techniques", "Testing", "Therapeutic", "Time", "Vaccines", "Variant", "Viral", "Viral Proteins", "Virulence Factors", "Virus", "Virus Inhibitors", "analog", "base", "fighting", "high throughput screening", "inhibitor/antagonist", "insight", "lead optimization", "mRNA Transcript Degradation", "mutant", "pharmacophore", "small molecule", "small molecule inhibitor", "therapeutic target" ], "approved": true } }, { "type": "Grant", "id": "5512", "attributes": { "award_id": "3R01AI141953-03S2", "title": "Site Specific Immunophenotyping Assays of COVID19 Patients to Align with NIAID National Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19175, "first_name": "Inka I", "last_name": "Sastalla", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-01", "end_date": "2023-05-31", "award_amount": 76331, "principal_investigator": { "id": 19176, "first_name": "Nitin S", "last_name": "Baliga", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 954, "ror": "https://ror.org/02tpgw303", "name": "Institute for Systems Biology", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The NIAID national protocol intends to enroll at least 1000 COVID19 patients in a study designed to track infected patients through tracking, over time, their immune responses, viral load, and a variety of multi-omic analytes that can provide deep insights into how infection by SARS-CoV-2 is revealed in host defense responses and disease- perturbed networks. At the heart of this study is the establishment of high quality biorepositories that can be used to quantitatively assess viral load, quantitatively interrogate viable PBMCs, and permit direct comparisons between different patients and different time points of disease progression. The nature of the infection, with highly differential patient outcomes, will eventually require significant computational efforts that can account for confounding factors such as co-morbidities, the influence of various therapies that are being broadly tested in these patients, etc. It will also certainly require both broadly available immune characterization tools that can be applied on all patient samples, but also specialized tools that can be used to inform the interpretation of the general analytics. In this project, we propose to integrate two sets of immune cell characterizations into the national NIAID effort. Those characterizations include single cell, functional phenotyping of select immune cell classes via an analysis designed to quantitate the levels of 35 secreted proteins from up to 2000 single cells of a given immune cell type. The second characterization is based upon reducing proteins from the SARS-CoV-2 into peptide antigen-major histocompatibility complex (pMHC) libraries that can be used to identify SARS-CoV- 2 antigen-specific CD8+ and CD4+ T cell populations from isolated, viable PBMCs. These assays provide deep and complementary information that will significantly inform the interpretation of the immune phenotyping assays that constitute the COREs of the NIAID study.", "keywords": [ "2019-nCoV", "Alleles", "Antibodies", "Antigens", "Biological Assay", "Biotechnology", "Blood", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "COVID-19 assay", "COVID-19 patient", "Cells", "Cellular Assay", "Clinical", "Computing Methodologies", "Coupled", "DNA", "Disease", "Disease Progression", "Enrollment", "Funding", "Heart", "Host Defense", "Immune", "Immune response", "Immunophenotyping", "Immunotherapy", "Infection", "Institutes", "Institutional Review Boards", "Investigation", "Joints", "Label", "Libraries", "Link", "Major Histocompatibility Complex", "Medical center", "National Institute of Allergy and Infectious Disease", "Nature", "Participant", "Patient-Focused Outcomes", "Patients", "Peptides", "Peripheral Blood Mononuclear Cell", "Pharmaceutical Preparations", "Phenotype", "Population", "Proteins", "Protocols documentation", "Reporting", "Research Design", "Research Personnel", "SARS-CoV-2 antigen", "SARS-CoV-2 infection", "Sampling", "Scanning", "Scientist", "Site", "Surface", "Surveys", "Systems Biology", "T-Cell Receptor Genes", "T-Lymphocyte", "Technology", "Testing", "Time", "Viral Load result", "Work", "antigen-specific T cells", "base", "biobank", "cell type", "cohort", "comorbidity", "defense response", "design", "insight", "multiple omics", "nasal swab", "patient response", "patient subsets", "receptor", "recruit", "response", "tool", "transcriptome sequencing" ], "approved": true } }, { "type": "Grant", "id": "5530", "attributes": { "award_id": "3P01AG041710-07S1", "title": "Health and Aging in Africa: Longitudinal Studies of an INDEPTH Community", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 19216, "first_name": "MINKI", "last_name": "CHATTERJI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2013-09-15", "end_date": "2022-05-31", "award_amount": 697533, "principal_investigator": { "id": 19217, "first_name": "LISA F", "last_name": "BERKMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 961, "ror": "", "name": "HARVARD SCHOOL OF PUBLIC HEALTH", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa (HAALSI) study examines biological, social, and economic determinants of disease and their effects on functional, health and cognitive outcomes among an aging population in South Africa. The emergence of the COVID-19 pandemic has profoundly impacted South Africa over the last 9 months, leading to stringent government lockdowns and widespread community transmission of SARS-CoV-2. COVID-19 has been demonstrated to be of particular risk to older adults around the world, especially those with underlying conditions including dementia and cardiometabolic disease. Gathering data on COVID-19 and accounting for the impact of this important public health crisis on personal and population health will be essential to fulfill the aims of the HAALSI P01 parent grant. In particular, Project 1’s aims focus on predictors and consequences of Alzheimer’s disease and related dementias (ADRD), attempting to identify diseases and social conditions that increase risk for cognitive impairment and decline. By leveraging the depth of longitudinal data available on the HAALSI cohort, including data on social and economic conditions, biomarkers, cognitive function, chronic conditions including HIV/AIDS and cardiometabolic disease, and genetic risks, as well as a subsample with MRIs and in-depth dementia assessments, we have a unique opportunity for novel research on causal relationships between dementia and COVID-19. Our research will facilitate better understanding of who is at risk of COVID-19 and why, and what the longer-term impacts might be on cognitive health of the cohort. We have two specific analytic aims to support these goals: (1) To assess how cognitive and genetic factors related to ADRD influence risk for SARS-CoV-2 infection and COVID-19 severity; and (2) To evaluate biological and socioeconomic pathways through which the COVID-19 pandemic may influence cognitive function, cognitive change, and incident dementia. To fulfill these aims we will utilize our planned Wave 3 survey to capture cognitive outcomes, and supplement existing HAALSI data with (1) a telephone survey to capture individual experiences during the COVID-19 pandemic; and (2) serological assays to assess SARS-CoV-2 infection. The telephone survey instrument has been harmonized with HRS sister study COVID modules to allow for cross national comparisons on COVID-19 exposures, health behaviors, and social consequences. Venous blood for SARS-CoV-2 serological assays will be collected during the planned HAALSI Wave 3 fieldwork in 2021, using tried-and-tested practices already in place in the Agincourt, field setting, in South Africa. We expect that this project will provide insight into mechanisms through which dementia and APOE genotype leads to SARS-CoV-2 infection and severe illness, and insight into the biological and socioeconomic pathways through which the COVID-19 pandemic may influence cognitive function, cognitive change and incident dementia. Our data collection and analyses will contribute to a better understanding of how COVID-19 impacts vulnerable populations in South Africa, regionally and around the world.", "keywords": [ "2019-nCoV", "AIDS/HIV problem", "Acceleration", "Accounting", "Address", "Affect", "Africa", "African", "Aging", "Alzheimer&apos", "s disease related dementia", "Behavior", "Biological", "Biological Markers", "Blood", "COVID-19", "COVID-19 pandemic", "COVID-19 severity", "Cardiometabolic Disease", "Cardiovascular Diseases", "Cerebrovascular Disorders", "Chronic", "Clinical Data", "Cognition", "Cognitive", "Communities", "Data", "Data Analyses", "Data Collection", "Dementia", "Disease", "Distress", "Economic Conditions", "Economics", "Education", "Elderly", "Environment", "Event", "Funding", "Future", "Genetic", "Genetic Predisposition to Disease", "Genetic Risk", "Genotype", "Goals", "Government", "Handwashing", "Health", "Health behavior", "Impaired cognition", "Incidence", "Individual", "Infection", "Lead", "Life", "Link", "Longitudinal Studies", "Longitudinal cohort", "Masks", "Neurocognitive", "Neurologic Effect", "Onset of illness", "Outcome", "Participant", "Pathway interactions", "Pattern", "Personal Satisfaction", "Physical Function", "Policies", "Population", "Prevalence", "Public Health", "Research", "Risk", "Risk Factors", "Rural", "SARS-CoV-2 antibody", "SARS-CoV-2 infection", "SARS-CoV-2 transmission", "Sampling", "Serology test", "Severities", "Severity of illness", "Shock", "Sister", "Site", "Social Conditions", "Social Distance", "Social Network", "South Africa", "Structure", "Subgroup", "Surveys", "Symptoms", "System", "Telephone", "Testing", "Venous", "Virus", "Vulnerable Populations", "aging population", "apolipoprotein E-4", "base", "caregiving", "cognitive change", "cognitive function", "cognitive impairment no dementia", "cognitive reserve", "cohort", "comorbidity", "coronavirus disease", "dementia risk", "disorder risk", "economic determinant", "experience", "global health", "health difference", "individual variation", "insight", "mortality", "novel", "pandemic disease", "parent grant", "population health", "response", "rural South Africa", "severe COVID-19", "social", "social determinants", "social vulnerability", "sociodemographics", "socioeconomics" ], "approved": true } }, { "type": "Grant", "id": "10277", "attributes": { "award_id": "1R44AI165129-01A1", "title": "New Technology for High-Resolution Antibody Profiling for SARS-CoV-2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 9207, "first_name": "Michael", "last_name": "Minnicozzi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-19", "end_date": "2024-07-31", "award_amount": 978625, "principal_investigator": { "id": 26235, "first_name": "Mark", "last_name": "Lim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1908, "ror": "", "name": "AMBERGEN, INC", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Summary/Abstract The SARS-CoV-2 virus has infected to date 35 million and killed over 600,000 persons in the U.S. alone. Despite initial success of the vaccines, the emergence of increasingly more infectious variants such as the delta variant, coupled with vaccine hesitancy and insufficiently effective therapies, has resulted in a continued and deepening national and world-wide pandemic crisis. Moreover, a significant fraction of COVID-19 patients (~35%), even those who are initially asymptomatic, suffer long-term debilitating effects (“long-COVID”). Recent reports correlate the structure of specific SARS-CoV-2 induced antibodies with potentially lethal proinflammatory responses in acute COVID-19. Studies have also linked the antibody response to long-COVID. Moreover, the nature of the antibody response to vaccination correlates with breakthrough infections. Thus, the ability to rapidly perform high- resolution, highly multiplexed antibody response profiling can provide an essential tool, ultimately leading to more effective diagnostics, prognostics, vaccines and treatments for both acute and long-term disease. However, current antibody profiling methods produce a very limited view of the humoral repertoire. To address this unmet need, AmberGen proposes to further develop in Phase II its mass spectrometric bead-array technology for in-depth immune-profiling, termed PC-BAMS-IP™. This will provide researchers with a new and powerful tool for high- resolution antibody profiling which unlike current technology facilitates 2-dimensions of multiplexing. This is accomplished using arrayed photocleavable mass-tag (PC-MT) encoded beads bearing viral antigens to bind serum antibodies, along with a range of PC-MT encoded probes to simultaneously measure the full breadth of bead-bound antibody types. Mass spectrometry imaging (MSI) of the bead-arrays facilitates the decoding of thousands of different PC-MTs, thereby revealing the full complexity of the antibody response and a means to correlate it with disease severity/outcome. Feasibility studies focused on SARS-CoV-2 demonstrate the ability of PC-BAMS-IP™ to perform simultaneous 2-dimensional antibody profiling of both the Fab traits (antigen binding function) and Fc traits (immune effector function). The proposed 2-year Phase II project will expand on this progress, including: i) design, synthesis and evaluation of 25 plug-and-play PC-MT encoded beads for SARS-CoV-2 antigen immobilization and 25 PC-MT probes to simultaneously query a range of Fc traits of the bead-bound serum antibodies; ii) initial validation of the PC-BAMS-IP™ assay using control and COVID-19 convalescent sera, including comparison to Luminex® xMAP® technology, the existing gold-standard for 1-dimensional multiplex antibody profiling; and iii) demonstrate that PC-BAMS-IP™ can distinguish severe and mild COVID-19. This work will be facilitated by our continued collaboration with leading experts including Prof. Cathy Costello (BU, world- renowned mass spectrometry expert), Dr. Jason Amsden (Duke University, mass spectrometric instrument development), Prof. Rahm Gummuluru (BU, Vice Chair of Microbiology, a leading virologist), and Prof. Plamen Ivanov (BU, Director, Keck Laboratory for Network Physiology, advanced statistical physics).", "keywords": [ "2019-nCoV", "Acute", "Address", "Analysis of Variance", "Antibodies", "Antibody Response", "Antigens", "Binding", "Biological Assay", "Boston", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "Characteristics", "Classification", "Cohort Analysis", "Collaborations", "Coupled", "Cross Reactions", "Device or Instrument Development", "Diagnostic", "Dimensions", "Disease", "Epitopes", "Evaluation", "Feasibility Studies", "Fluorescence", "Gold", "Human", "IgG1", "Immobilization", "Immune", "Immune response", "Immunoglobulin Isotypes", "Individual", "Label", "Laboratories", "Link", "Long COVID", "Mass Spectrum Analysis", "Measures", "Methods", "Microbiology", "Modeling", "Nature", "Noise", "Outcome", "Patients", "Persons", "Phase", "Physics", "Physiological", "Physiology", "Play", "Postdoctoral Fellow", "ROC Curve", "Reagent", "Reporting", "Research", "Research Personnel", "Resolution", "SARS-CoV-2 B.1.617.2", "SARS-CoV-2 antibody", "SARS-CoV-2 antigen", "SARS-CoV-2 exposure", "Sampling", "Sensitivity and Specificity", "Serology", "Serum", "Severity of illness", "Signal Transduction", "Structure", "System", "Technology", "Universities", "Vaccination", "Vaccines", "Validation", "Variant", "Viral Antigens", "Virus", "Work", "antigen binding", "base", "breakthrough infection", "cohort", "design", "distinguished professor", "effective therapy", "glycosylation", "improved", "mass spectrometric imaging", "medical schools", "new technology", "pandemic disease", "pathogen", "predictive modeling", "professor", "prognostic", "response", "severe COVID-19", "success", "tool", "trait", "two-dimensional", "vaccine hesitancy", "virus infection mechanism" ], "approved": true } }, { "type": "Grant", "id": "5386", "attributes": { "award_id": "3U01AG009740-33S1", "title": "Health and Retirement Study: Years 29-34", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 18863, "first_name": "John", "last_name": "Phillips", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1990-09-25", "end_date": "2023-12-31", "award_amount": 990154, "principal_investigator": { "id": 18864, "first_name": "DAVID R.", "last_name": "WEIR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "This competing continuation proposal for Years 29-34 of the Health and Retirement Study (HRS) cooperative agreement is in response to NIA RFA #AG-18-005. The primary aim of the HRS is to design, collect and distribute longitudinal multi-disciplinary data to support research on aging and the health and well- being of the older population. This proposal seeks to collect three additional waves of panel data, continue collection of venous blood specimens, implement the next scheduled refreshment by adding the first Gen-X cohort in 2022, continue to conduct off-year mail surveys, and implement cost-saving innovations, including an internet mode for Core data collection. It will continue the same expanded minority oversample design for the Gen-X cohort as was implemented in 2010 and 2016 for the baby boom cohorts in which half the sample consists of traditionally underrepresented minorities. The new Gen-X cohort will be fully integrated into the HRS design, including collection of biomarkers, DNA, and linkage consents to Social Security and other records as appropriate. This parent project will provide sample, data, and coordinate fully with the separate proposal to repeat the Harmonized Cognitive Assessment Protocol dementia study. HRS provides a uniquely rich, nationally representative longitudinal dataset for the community of scientific and policy researchers who study the health and demography of aging. It provides a research data base that can simultaneously support cross-sectional descriptions of the U.S. population age 50+, longitudinal studies of a given cohort over a substantial period of time and research on cross-cohort trends. The HRS project creates a data system extending beyond the core survey data. One component of this extended data system consists of linkages to administrative data, including Social Security earnings and benefit records, Medicare utilization and diagnostic records, including Minimum Data Set and Medicaid records, employer pension records, Veterans Health Administration data and the National Death Index. We plan to expand access to these secure data through secure enclaves. Another component is genome-wide genotyping data from consenting respondents distributed through dbGaP and a new repository of blood samples including cryopreserved cells. HRS provides public use data designed to allow the full power and creativity of America's scientific community to address the challenges of an aging population. HRS is making a significant impact on research on aging through investigator-initiated research which uses the HRS as an input without charge to researchers or granting agencies. Over 2,000 peer-reviewed journal publications have appeared, nearly 1,000 in the past six years. HRS also supports training of new scientists as over 400 doctoral dissertations have used HRS data.", "keywords": [ "Address", "Age", "Aging", "Americas", "Baby Booms", "Bibliography", "Biological Assay", "Biological Markers", "Biological Specimen Banks", "Blood", "Blood specimen", "Brazil", "Cessation of life", "Charge", "China", "Collaborations", "Collection", "Communities", "Complex", "Consent", "Consumption", "Cost Savings", "Country", "Creativeness", "Cryopreserved Cell", "DNA", "Data", "Data Collection", "Data Set", "Databases", "Decision Making", "Dementia", "Development", "Devices", "Diagnostic", "Documentation", "Elements", "England", "Enrollment", "Europe", "Exhibits", "Future", "Genetic", "Genotype", "Geography", "Grant", "Health", "Health and Retirement Study", "Income", "India", "Indonesia", "Information Systems", "International", "Internet", "Interview", "Investigator-Initiated Research", "Japan", "Journals", "Life Experience", "Longitudinal Studies", "Measurement", "Measures", "Medicaid", "Medicare", "Methods", "Mexico", "Minority", "Older Population", "Online Systems", "Peer Review", "Pensions", "Personal Satisfaction", "Persons", "Physical activity", "Policies", "Population", "Population Study", "Prevalence Study", "Protocols documentation", "Public Health", "Publications", "Records", "Research", "Research Design", "Research Personnel", "Research Support", "Respondent", "Rotation", "Sampling", "Schedule", "Scientist", "Secure", "Security", "Services", "Social Security", "Source", "South Africa", "Structure", "Surveys", "Time", "Training Support", "U-Series Cooperative Agreements", "Underrepresented Minority", "Update", "Venous", "Veterans Health Administration", "aging demography", "aging population", "cognitive ability", "cognitive function", "cognitive testing", "cohort", "cost", "cost effective", "data access", "data quality", "data resource", "database of Genotypes and Phenotypes", "design", "distributed data", "genome-wide", "improved", "indexing", "innovation", "longitudinal dataset", "member", "multidisciplinary", "neuroimaging", "parent project", "prospective", "psychosocial", "recruit", "repository", "research and development", "response", "screening", "sustained attention", "symposium", "trend", "web site" ], "approved": true } }, { "type": "Grant", "id": "10269", "attributes": { "award_id": "1R21AI170246-01", "title": "A participant-derived xenograft mouse model to study T-cell-mediated viral control and mRNA vaccine strategies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22685, "first_name": "Diane M.", "last_name": "Lawrence", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-12", "end_date": "2024-07-31", "award_amount": 254250, "principal_investigator": { "id": 26222, "first_name": "R. Brad BRAD", "last_name": "Jones", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Although modern therapies have dramatically improved the outlooks for people living with HIV they are unable to cure infection, leaving these individuals burdened by a lifelong commitment to antiretroviral (ARV) medication. For any given individual, maintaining lifelong adherence to medication can present substantial challenges. Moreover, many people do not have access to these expensive medications - in particular those living in resource-limited settings. Furthermore, efforts to end the HIV epidemic have suffered from the lack of effective preventative or therapeutic vaccines – biomedical tools which have played critical roles in the elimination of other epidemics, such as smallpox. Recent years have seen important advances in harnessing the antibody arm of the immune system towards these aims, though substantial challenges still exist. The T-cell arm of the immune system, which specializes in the recognition and elimination of virus infected cells, holds great promise to contribute to these efforts, but has lagged behind in development. This can be attributed – in part – to substantial limitations in the suitability of currently available pre-clinical animal models for the study of T-cell responses. For example, the property of major histocompatibility (MHC) restriction means that the ways in which the virus- infected cells of a rhesus macaque will recognize a virus-infected cell differ from the way they would be recognized by a given human. The current proposal aims to build upon compelling preliminary results, in which we have observed that a relatively simple, but powerful, modification of a humanized mouse model solves many of the key issues that have limited utility to date. Namely, we present a mouse model that can be stably engrafted with immune cells (PBMC) from HIV-infected or uninfected adults, without inducing graft versus host disease (GvHD). The use of adult cells both avoids the need for fetal tissue. In this project, we will test whether HIV- specific T-cell responses arise naturally in this mouse model, and whether these play a role in suppressing viral replication. We will then test whether we are able to induce HIV-specific T-cell responses in uninfected animals using an mRNA vaccine technology, similar to that employed against COVID-19. Finally, we will test whether vaccine-induced responses can control viral replication. If successful, this will result in a novel small animal model in which we can rapidly test and optimize HIV vaccination strategies using a mRNA platform. We believe that this will facilitate the translation of optimal approaches to clinical trials.", "keywords": [ "Address", "Adherence", "Adult", "Animal Model", "Animals", "Anti-Retroviral Agents", "Antibodies", "Antigen-Presenting Cells", "CD8-Positive T-Lymphocytes", "COVID-19", "Cells", "Cellular Assay", "Clinical Trials", "Complex", "Data", "Development", "Engraftment", "Epidemic", "Equipment", "Evaluation", "Fetal Tissues", "Foundations", "HIV", "HIV Infections", "Histocompatibility", "Human", "Immune", "Immune system", "Immunization", "Immunotherapeutic agent", "Individual", "Infection", "Knockout Mice", "Macaca mulatta", "Mediating", "Messenger RNA", "Methods", "Modeling", "Modernization", "Modification", "Mus", "Mutation", "Operative Surgical Procedures", "Participant", "Peripheral Blood Mononuclear Cell", "Persons", "Pharmaceutical Preparations", "Plasma", "Play", "Preventive vaccine", "Property", "Publications", "RNA vaccination", "RNA vaccine", "Reporting", "Resource-limited setting", "Robotics", "Role", "Smallpox", "Study models", "Suggestion", "T cell response", "T cell therapy", "T-Lymphocyte", "Technical Expertise", "Technology", "Testing", "Translations", "Vaccination", "Vaccines", "Viral", "Viral Load result", "Viral load measurement", "Viremia", "Virus", "Virus Replication", "Work", "Xenograft Model", "Xenograft procedure", "anti-viral efficacy", "arm", "base", "cost effectiveness", "experience", "experimental study", "flexibility", "gene product", "graft vs host disease", "humanized mouse", "immunogenicity", "improved", "in vivo", "lipid nanoparticle", "memory CD4 T lymphocyte", "mouse model", "next generation", "novel", "pre-clinical", "response", "therapeutic development", "therapeutic vaccine", "tool", "vaccination strategy", "vaccine response", "vaccine strategy" ], "approved": true } }, { "type": "Grant", "id": "10325", "attributes": { "award_id": "1R43CK000679-01", "title": "Lateral Flow-Electrochemiluminescent (LF-ECL) Test Strips and Portable Reader for Ultrasensitive Foodborne Pathogen Detection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 225000, "principal_investigator": { "id": 26285, "first_name": "John", "last_name": "Bruno", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1916, "ror": "", "name": "NANOHMICS, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract Nanohmics proposes to couple the extreme sensitivity of electrochemiluminescence (ECL) from traditional ruthenium trisbipyridine (Ru(bpy)3) or even more promising quantum dot (Qdot)-based ECL sensitivity with the portability, convenience and speed (~ 15 minutes) of lateral flow (LF) test strips to produce a menu of ultrasensitive assays for detection of the major foodborne pathogenic bacteria and viruses. LF strip assays are known for being rapid, highly affordable, and facile onsite diagnostics, but generally lack sensitivity and may miss detection of foodborne pathogens (false negative results) at low levels even in time-consuming enrichment cultures. In some cases, LF strip developers have turned to fluorescence for added sensitivity. But, fluorescence has innate autofluorescent background from the excitation of other biological materials in samples, thus limiting its sensitivity. And although chemiluminescence (CL) can be ultrasensitive due to its initial black background and high signal to noise ratios (SNRs), CL is difficult to control spatially on a test strip and requires temporal delays to allow it to reach stable equilibrium prior to measurement which limits reproducibility. However, ECL is simple to control by controlling the working electrode voltage (only about 1.25V), thus enabling battery-operated handheld readers too. ECL can amplify or accrue the signal over time each time the Ru(bpy)3 redox “wheel” is turned electrically to release another red photon, thus giving sensitivity comparable to radioisotopic methods when the ECL signal is integrated over time. Newer Qdot-based ECL techniques promise as much as a million- fold increase in ECL over Ru(bpy)3-antibody or aptamer tags as well. Thus, Nanohmics proposes to build on its recent CDC- funded Phase I and DoD/OSD-funded Phase II SBIR contracts that are enabling it to develop highly sensitive antibody LF test strips for Influenza A/B and SARS-CoV-2 fluorescent and ECL LF assays using Qdots. These Qdot-LF test strips will be compared with antibody- and DNA aptamer-Ru(bpy)3-based LF test strips in terms of ECL output and limits of detection (LOD) for foodborne pathogens (initially Listeria and Salmonella) in Phase I. The winning LF strip design will be used for development of a portable ECL LF test strip reader and more foodborne bacterial and virus assays in Phase II to deliver to the public the most sensitive and rapid handheld onsite foodborne pathogen tests to aid in rapid detection and control of foodborne disease outbreaks.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 3, "pages": 1392, "count": 13920 } } }